Searched for
DRL EARNINGS PREVIEW
Dr Reddy’s Q2 Preview: High base to play spoilsport, outlook for US, Russia in focusDr Reddy’s topline will continue to be aided by sales contributions from the cancer drug Revlimid’s generic. While the overall revenue grow...- Sensex, Nifty snap 3-day losing run; 6 factors that led the rallyAfter settling with cuts for 3 sessions, the 30-share pack Sensex advanced on Friday, rising 412.23 points or 0.70% to settle at 59,447.18....
- DRL Q3 Results Preview: Profit may grow 25% YoY; margin likely to fallEdelweiss sess profit rising 26.5 per cent YoY to Rs 780 crore. It sees sales rising 12.2 per cent YoY to Rs 5,531 crore. The brokerage see...
- Load More